A grieving person was evacuated.
Europa investiga si aprueba o no esta vacuna.
Photo: EFE
The European Medicines Agency (EMA) Investigates the risk of developing thromboembolism with the vaccine of the COVID-19 of Janssen, a subsidiary of the Johnson & Johnson branch, to receive a “security signal” related to four cases of severe coagulation coagulation is prepared.
As recently confirmed by the EMA, and the meetings held by the Security Committee (PRAC) since last March have been held by its experts, it has initiated a “revision” of cases to investigate cases of thromboembolic events or formation of known blood clots. Janssen.
The EMA analyzes data on four cases of severe blood clotting with placental abruption in patients who have received this vaccine in advance, one of them during the clinical trial and three during the use of Janssen in United States, by those who died .
“We are informing you about a ‘security signal’, but at present it is not clear if there is a causal association between the vacancy with Janssen and these affections. The PRAC is investigating these cases and will decide if a regulatory action is needed, which generally consists of an update of the product information ”, the EMA stated in a summary of the PRAC meetings this week.
Although no receipt has been made for a good EMA visit, Janssen’s vaccine has not been used in the European Union (EU) and has been withdrawn at the dose of pharmaceuticals, at the moment, only is used in the United States with an emergency use permit for immunization against COVID-19.
It is hoped that the first injections of this vaccine will take place in European countries from April 19, according to the announcement of the pharmaceutical price, which will reach 55 million units in the second quarter of this year.
Last week, the EMA concluded an investigation into the existence of a “possible angle” between the AstraZeneca vaccine and dozens of cases of unusual blood clots detected in the posterior semen in the injection, and the decision to remove it is very short. in the UE the 29th of January.
Without embargo, and many variants European states are limiting their use in person with superior editions in the 60s, the EMA has not identified a determined risk factor, such as edema, sex or a specific historical clinic, which explains thromboembolism reported , and recommends maintaining its use in vacancy campaigns because of its benefits against COVID-19 over the risk of its secondary effects.
© 360 TELECOM CORPORATION